Evolent Health Sees Unusually High Options Volume (EVH)

Evolent Health Inc (NYSE:EVH) was the recipient of unusually large options trading on Wednesday. Traders acquired 2,669 call options on the stock. This represents an increase of approximately 4,205% compared to the typical volume of 62 call options.

Evolent Health stock opened at $13.98 on Friday. The firm has a market cap of $1.20 billion, a P/E ratio of -19.97 and a beta of 1.38. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.50 and a quick ratio of 2.50. Evolent Health has a one year low of $13.61 and a one year high of $29.05.

Institutional investors have recently bought and sold shares of the stock. Tygh Capital Management Inc. increased its position in Evolent Health by 88.5% during the fourth quarter. Tygh Capital Management Inc. now owns 337,519 shares of the technology company’s stock valued at $6,734,000 after acquiring an additional 158,482 shares during the last quarter. Macquarie Group Ltd. increased its position in Evolent Health by 33.5% during the third quarter. Macquarie Group Ltd. now owns 304,338 shares of the technology company’s stock valued at $8,643,000 after acquiring an additional 76,345 shares during the last quarter. Jane Street Group LLC purchased a new stake in Evolent Health during the third quarter valued at $205,000. Oppenheimer Asset Management Inc. increased its position in Evolent Health by 15.8% in the fourth quarter. Oppenheimer Asset Management Inc. now owns 155,607 shares of the technology company’s stock worth $3,104,000 after buying an additional 21,233 shares in the last quarter. Finally, Granite Investment Partners LLC increased its position in Evolent Health by 5.2% in the third quarter. Granite Investment Partners LLC now owns 662,765 shares of the technology company’s stock worth $18,822,000 after buying an additional 32,846 shares in the last quarter.

Several research firms have recently weighed in on EVH. Zacks Investment Research cut Evolent Health from a “buy” rating to a “hold” rating in a research note on Thursday. ValuEngine upgraded Evolent Health from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $37.00 price target on shares of Evolent Health in a research note on Monday, December 31st. One research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $31.00.

WARNING: “Evolent Health Sees Unusually High Options Volume (EVH)” was published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US and international copyright & trademark laws. The original version of this news story can be accessed at https://www.chaffeybreeze.com/2019/02/22/evolent-health-sees-unusually-high-options-volume-evh.html.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, provides health care delivery and payment solutions in the United States. The company operates as a managed services firm that supports health systems and physician organizations in migration toward value-based care and population health management.

See Also: How to interpret a stock’s beta number

Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply